Jazz Pharmaceuticals closes $1.25B notes deal, trading cheap capital for dilution risk

The concurrent buyback partially offsets the equity overhang but uses cash and reduces remaining authorization. Jazz repurchased approximately $225 million of shares at $249.29, leaving roughly $1.001 billion of gross financing proceeds before other corporate uses; the filing explicitly says the repurchase reduced the remaining amount authorized under its existing buyback program. (Item 1.01) Net versus expectations, this is best classified as a completed, already-known capital-structure transaction: attractive low-cost funding and an immediate buyback, balanced by higher debt and potential future dilution.